Trial Profile

Metabolomic Profiling of Multiple Myeloma patients treated with Carfilzomib

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary)
Indications Multiple myeloma
Focus Adverse reactions

Most Recent Events

24 Jun 2020 Results assessing differential expressions of miR-17 and complement factor D in carfilzomib-related cardiotoxicity in patients with multiple myeloma presented at the 111th Annual Meeting of the American Association for Cancer Research - II
15 Dec 2019 New trial record
18 Nov 2019 Results presented at the American Heart Association Scientific Sessions 2019

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com